| Autor: |
de Pablos-Rodríguez P; Department of Urology, Instituto Valenciano de Oncología (IVO), 46009 Valencia, Spain.; Doctoral School of University of Las Palmas de Gran Canaria (ULPGC), 35001 Las Palmas de Gran Canaria, Spain., Del Pino-Sedeño T; Canary Islands Health Research Institute Foundation (FIISC), 38320 Santa Cruz de Tenerife, Spain.; Evaluation Unit of the Canary Islands Health Service (SESCS), 38109 Santa Cruz de Tenerife, Spain.; Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), 38109 Santa Cruz de Tenerife, Spain., Infante-Ventura D; Canary Islands Health Research Institute Foundation (FIISC), 38320 Santa Cruz de Tenerife, Spain.; Evaluation Unit of the Canary Islands Health Service (SESCS), 38109 Santa Cruz de Tenerife, Spain., de Armas-Castellano A; Canary Islands Health Research Institute Foundation (FIISC), 38320 Santa Cruz de Tenerife, Spain.; Evaluation Unit of the Canary Islands Health Service (SESCS), 38109 Santa Cruz de Tenerife, Spain., Ramírez Backhaus M; Department of Urology, Instituto Valenciano de Oncología (IVO), 46009 Valencia, Spain., Ferrer JFL; Department of Clinical Sciences, University of Las Palmas de Gran Canaria (ULPGC), 35001 Las Palmas de Gran Canaria, Spain., de Pablos-Velasco P; Department of Endocrinology and Nutrition, University Hospital of Gran Canaria Doctor Negrín, 35012 Las Palmas de Gran Canaria, Spain.; Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria (ULPGC), 35001 Las Palmas de Gran Canaria, Spain., Rueda-Domínguez A; Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), 38109 Santa Cruz de Tenerife, Spain.; Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, 29590 Malaga, Spain.; Research Network on Health Services in Chronic Diseases (REDISSEC), Carlos III Health Institute, 28029 Madrid, Spain., Trujillo-Martín MM; Canary Islands Health Research Institute Foundation (FIISC), 38320 Santa Cruz de Tenerife, Spain.; Evaluation Unit of the Canary Islands Health Service (SESCS), 38109 Santa Cruz de Tenerife, Spain.; Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), 38109 Santa Cruz de Tenerife, Spain.; Research Network on Health Services in Chronic Diseases (REDISSEC), Carlos III Health Institute, 28029 Madrid, Spain. |
| Abstrakt: |
Prostate cancer (PCa) is the second most common cancer in men and the fifth leading cause of death from cancer. The possibility of sarcopenia being a prognostic factor in advanced PCa patients has recently become a subject of interest. The aim of the present study was to evaluate the prognostic value of sarcopenia in advanced prostate carcinoma. A systematic review was conducted in Medline, EMBASE, and Web of Science (March, 2021). The quality of studies was assessed using the Quality in Prognosis Studies tool. Meta-analyses for overall, cancer-specific, and progression-free survival were performed. Nine studies (n = 1659) were included. Sarcopenia was borderline associated with a shorter overall survival (HR = 1.20, 95% CI: 1.01, 1.44, P = 0.04, I2 = 43%) but was significantly associated with progression-free survival (HR = 1.61, 95% CI: 1.26, 2.06, P < 0.01; k = 3; n = 588). Available evidence supports sarcopenia as an important prognostic factor of progression-free survival in patients with advanced PCa. However, sarcopenia has a weak association with a shorter overall survival. The evidence on the role of sarcopenia in prostate-cancer-specific survival is insufficient and supports the need for further research. Patient summary: The literature was reviewed to determine whether the loss of muscle mass (sarcopenia) affects the survival in patients with advanced PCa. Patients with advanced PCa and sarcopenia were found to have a shorter progression-free survival (the length of time during and after treatment of a cancer that the patient lives with the disease but it does not get worse), but sarcopenia did not have much influence on the overall survival and cancer-specific survival (the length of time from either the date of diagnosis or the start of treatment to the date of death due to the cancer). |
